Aneyefor News

(Albany, US) On October 30, 2026, DelveInsight’s “Peripheral T-Cell Lymphoma Pipeline Insights 2026” report provides comprehensive insights about 30+ companies and 32+ pipeline drugs in the Peripheral T-Cell Lymphoma pipeline landscape. It covers the Peripheral T-Cell Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Peripheral T-Cell Lymphoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Peripheral T-Cell Lymphoma Pipeline @ https://www.delveinsight.com/sample-request/peripheral-t-cell-lymphomas-ptcl-pipeline-insight

Key Takeaways from the Peripheral T-Cell Lymphoma Pipeline Report

• On October 28, 2026, National Cancer Centre Singapore updated its POLAR clinical trial evaluating pembrolizumab in combination with olaparib in patients with relapsed or refractory Peripheral T-Cell Lymphoma. The study aims to investigate the efficacy and safety of this combination, with key endpoints including objective response rate, progression-free survival, overall survival, and treatment-related adverse events. The trial is exploring the potential of combining immune checkpoint inhibition with PARP inhibition to improve treatment outcomes in patients with difficult-to-treat PTCL.
• On October 13, 2026, Prescient Therapeutics Limited announced its September 2026 quarterly business update, highlighting the continued development of PTX-100 for T-cell lymphomas. The company reported that PTX-100 had completed its Phase Ib expansion cohort study, demonstrating encouraging efficacy and safety findings in patients with T-cell lymphoma. Prescient is evaluating further clinical development opportunities in Peripheral T-Cell Lymphoma (PTCL), with additional studies expected to be considered following selection of the recommended Phase II dose in its ongoing cutaneous T-cell lymphoma program. PTX-100 is an investigational geranylgeranyl transferase type I (GGT-I) inhibitor designed to interfere with cancer-related signaling pathways.
• On October 15, 2026, Yale University updated its Phase II clinical study evaluating pembrolizumab in combination with brentuximab vedotin in patients with relapsed or refractory CD30-positive T-cell lymphoma, including Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma. The open-label, multicenter study aims to enroll approximately 43 patients and assess the antitumor activity of the combination, with an objective response rate of approximately 65% as the anticipated outcome. The study will also evaluate treatment safety, tolerability, and response durability.
• DelveInsight’s Peripheral T-Cell Lymphoma pipeline report depicts a robust space with 30+ active players working to develop 32+ pipeline therapies for Peripheral T-Cell Lymphoma treatment.
• The leading Peripheral T-Cell Lymphoma Companies include Corvus Pharmaceuticals, Dizal Pharmaceuticals, Innate Pharma, Secura Bio, Shanghai YingLi Pharmaceutical, Prescient Therapeutics, CellCentric, BioInvent International, HUYABIO International, Pfizer, Kyowa Kirin, Takeda Pharmaceutical, Daiichi Sankyo, Citius Pharmaceuticals, Acrotech Biopharma, Sobi and others.
• Promising Peripheral T-Cell Lymphoma Pipeline Therapies such as XNW5004, BR101801, FG-M131, KK2223 and others.

Stay ahead with the most recent Peripheral T-Cell Lymphoma pipeline outlook with DelveInsight @ Peripheral T-Cell Lymphoma Treatment Drugs

The Peripheral T-Cell Lymphoma Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Peripheral T-Cell Lymphoma Pipeline Report also highlights the unmet needs with respect to the Peripheral T-Cell Lymphoma.

Peripheral T-Cell Lymphoma Overview

Peripheral T-cell lymphomas (PTCLs) are a rare and heterogeneous group of aggressive non-Hodgkin lymphomas arising from mature, post-thymic T cells or, in some entities, natural killer (NK) cells. More than 30 distinct entities are recognized across nodal, extranodal, leukemic and cutaneous categories, including PTCL-not otherwise specified (PTCL-NOS), angioimmunoblastic/T-follicular helper (TFH) lymphomas and anaplastic large-cell lymphoma (ALCL). PTCLs generally have an aggressive clinical course and are frequently diagnosed at an advanced stage. They account for approximately 10–15% of non-Hodgkin lymphomas, although their incidence varies geographically.

Peripheral T-Cell Lymphoma Emerging Drugs Profile

• XNW5004: Evopoint Biosciences

XNW5004 is an investigational, orally administered selective EZH2 inhibitor developed by Evopoint Biosciences, designed to inhibit both wild-type and mutant EZH2 and suppress H3K27 trimethylation, thereby promoting cell-cycle arrest and apoptosis in tumor cells. In September 2024, it received Breakthrough Therapy Designation (BTD) from China’s CDE for relapsed/refractory (R/R) PTCL based on clinical data demonstrating promising activity. In a Phase I/II study, XNW5004 achieved an ORR of 70.3% in PTCL at the 1,200 mg BID dose, with median PFS of 15.7 months and median duration of response of 13.9 months. Currently, the drug is in Phase III study evaluating XNW5004 versus chidamide in R/R PTCL.

• BR101801: Boryung Pharmaceutical

BR101801 (bosmolisib) is an oral, investigational triple inhibitor of PI3K-?, PI3K-? and DNA-PK being developed by Boryung Pharmaceutical for relapsed/refractory (R/R) peripheral T-cell lymphoma (PTCL). By simultaneously inhibiting PI3K signaling and DNA-PK, the drug is designed to suppress tumor-cell growth, induce cell-cycle arrest and apoptosis, and reduce the stability of oncogenic c-Myc. In an earlier Phase I study, BR101801 demonstrated an ORR of 31.6% and a complete response rate of 21.1% in evaluable R/R PTCL patients, supporting further development. The Phase II study is designed to evaluate BR101801 monotherapy in patients with R/R PTCL with 200 mg once daily being the established recommended Phase II dose.

• FG-M131: FutureGen Biopharmaceutical

FG-M131 is an investigational antibody–drug conjugate (ADC) targeting T-cell receptor beta constant region 1 (TRBC1), a component of the ?? T-cell receptor complex. By selectively targeting TRBC1-positive malignant T cells while potentially sparing TRBC2-positive normal T cells, it represents a novel targeted approach for T-cell malignancies. The drug is being evaluated in a multicenter, open-label Phase I/II study in patients with TRBC1-positive relapsed/refractory PTCL, assessing safety, pharmacokinetics and preliminary antitumor activity.

• KK2223: Kyowa Kirin

KK2223 is an investigational, first-in-class therapeutic developed by Kyowa Kirin for T-cell non-Hodgkin lymphomas, including relapsed/refractory PTCL and CTCL. It is being evaluated in a first-in-human, Phase I, open-label, multicenter study, evaluating intravenous KK2223 through dose-escalation and backfill cohorts. The trial is designed to assess safety, tolerability, pharmacokinetics and pharmacodynamics in patients with relapsed/refractory PTCL or CTCL. The study includes PTCL subtypes such as PTCL-NOS, nodal TFH lymphoma and ALCL, positioning KK2223 as an emerging investigational option for heavily pretreated T-cell malignancies.

The Peripheral T-Cell Lymphoma Pipeline Report Provides Insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Peripheral T-Cell Lymphoma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Peripheral T-Cell Lymphoma Treatment.
• Peripheral T-Cell Lymphoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Peripheral T-Cell Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Peripheral T-Cell Lymphoma market

Explore groundbreaking therapies and clinical trials in the Peripheral T-Cell Lymphoma Pipeline @ New Peripheral T-Cell Lymphoma Drugs

Peripheral T-Cell Lymphoma Companies

Corvus Pharmaceuticals, Dizal Pharmaceuticals, Innate Pharma, Secura Bio, Shanghai YingLi Pharmaceutical, Prescient Therapeutics, CellCentric, BioInvent International, HUYABIO International, Pfizer, Kyowa Kirin, Takeda Pharmaceutical, Daiichi Sankyo, Citius Pharmaceuticals, Acrotech Biopharma, Sobi and others.

Peripheral T-Cell Lymphoma Pipeline Report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
• Molecule Type

Peripheral T-Cell Lymphoma Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule
• Product Type

Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Peripheral T-Cell Lymphoma Market Drivers and Barriers

Scope of the Peripheral T-Cell Lymphoma Pipeline Report

• Coverage- Global
• Peripheral T-Cell Lymphoma Companies- Corvus Pharmaceuticals, Dizal Pharmaceuticals, Innate Pharma, Secura Bio, Shanghai YingLi Pharmaceutical, Prescient Therapeutics, CellCentric, BioInvent International, HUYABIO International, Pfizer, Kyowa Kirin, Takeda Pharmaceutical, Daiichi Sankyo, Citius Pharmaceuticals, Acrotech Biopharma, Sobi and others.
• Peripheral T-Cell Lymphoma Pipeline Therapies- XNW5004, BR101801, FG-M131, KK2223 and others.
• Peripheral T-Cell Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Peripheral T-Cell Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Peripheral T-Cell Lymphoma Therapies and clinical trials @ Peripheral T-Cell Lymphoma Companies, Key Products and Unmet Needs

Table of Contents

1. Introduction
2. Executive Summary
3. Peripheral T-Cell Lymphoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Peripheral T-Cell Lymphoma – DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. Peripheral T-Cell Lymphoma Collaboration Deals
9. Late Stage Products (Pre-registration)
10. XNW5004: Evopoint Biosciences
11. Late Stage Products (Phase III)
12. Mid Stage Products (Phase II)
13. BR101801: Boryung Pharmaceutical
14. Comparative Analysis
15. Early Stage Products (Phase I/II)
16. KK2223: Tr1X Inc.
17. Comparative Analysis
18. Peripheral T-Cell Lymphoma Key Companies
19. Peripheral T-Cell Lymphoma Key Products
20. Peripheral T-Cell Lymphoma Unmet Needs
21. Peripheral T-Cell Lymphoma Market Drivers and Barriers
22. Peripheral T-Cell Lymphoma Future Perspectives and Conclusion
23. Peripheral T-Cell Lymphoma Analyst Views
24. Peripheral T-Cell Lymphoma Key Companies
25. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: Ukraine
Website: https://www.delveinsight.com/report-store/peripheral-t-cell-lymphomas-ptcl-pipeline-insight